HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced that the U.S. Food and Drug Administration (FDA) has accepted its HeartBeam System into the Total Product Life Cycle Advisory Program (TAP) Pilot. The acceptance follows the receipt of Breakthrough Device Designation earlier this month and applies to the company’s 3D electrocardiogram (ECG) technology being developed to assess potential heart attacks outside traditional medical settings.
The TAP Pilot provides dedicated FDA advisors, expedited regulatory feedback, and access to healthcare providers, patient advocacy groups, and insurers to help accelerate development and patient access. For HeartBeam, this engagement could streamline the regulatory pathway for its heart attack assessment technology, which is not currently cleared for that indication. The company estimates the heart attack assessment market opportunity at approximately $15 billion within a broader cardiac platform opportunity exceeding $40 billion.
HeartBeam expects to seek FDA alignment on its multicenter pivotal study design in the coming months, with patient enrollment anticipated to begin in the first quarter of 2027. The study is intended to support a future regulatory submission expanding the HeartBeam System’s indications to include heart attack assessment. The company is also evaluating eligibility for the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, designed to accelerate Medicare access to eligible Breakthrough devices.
The HeartBeam System is not currently cleared for heart attack detection, and TAP participation does not guarantee future FDA authorization or insurance coverage. However, the program’s resources could help the company navigate the complex regulatory and reimbursement landscape more efficiently. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
For investors, the TAP acceptance signals potential acceleration in bringing a novel cardiac monitoring solution to market. The technology is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, enabling portable use wherever the patient is. This could redefine cardiac health management by allowing physicians to identify trends and acute conditions outside medical facilities. More details are available in the company’s newsroom at https://nnw.fm/BEAT, and the full press release can be viewed at https://nnw.fm/NdfEK.
The announcement was distributed via NetworkNewsWire, a specialized communications platform and one of 75+ brands within the Dynamic Brand Portfolio at IBN. NetworkNewsWire offers services including InvestorWire wire distribution, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms of use and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.
